Page 4 of 7
Where was this study done?
Study sites were in 17 countries.
Number of participants who received at least one dose
of the study medicines
Argentina 26
Belgium 12
Brazil 39
Canada 20
China 38
Denmark 15
France 39
Germany 40
Italy 37
Mexico 27
Russia 20
South Africa 18
Spain 44
Sweden 11
Taiwan 23
United Kingdom 20
United States 64
0 25 50 75
Number of participants
What were the main results of the study?
Study doctors collected blood samples and measured participantsâ€™ viral loads.
The study compared the number of participants in the two treatment groups, who had
a detectable viral load (50 c/mL or more) at Week 48.
One of 246 participants (less than 1%) in the DTG and 3TC group and three of
247 participants (1%) in the CAR group had a detectable viral load at Week 48.